The present study directly compared the antinociceptive and toxic effects of the neuronal
nicotinic receptor agonist
ABT-594 ((R)-5-(2-azetidinylmethoxy)-2-chloropyridine) with (-)-
nicotine and (+)-
epibatidine. Like (-)-
nicotine (0.8 and 1.6 mg/kg s.c.) and (+)-
epibatidine (0.005 and 0.01 mg/kg s.c.),
ABT-594 (0.05 and 0.1 mg/kg s.c.) increased response latencies in the hot-plate test in rats, indicating that it has antinociceptive activity. In contrast to (-)-
nicotine and (+)-
epibatidine,
ABT-594 did not cause rotarod impairment at antinociceptive doses but did cause
hypothermia and life-threatening adverse effects including
seizures.
ABT-594 (0.01 and 0.1 mg/kg i.v.) also produced a dose-dependent increase in blood pressure resembling that observed with (-)-
nicotine (0.03, 0.1 and 0. 03 mg/kg i.v.) and (+)-
epibatidine (0.001 and 0.003 mg/kg i.v.). Both the antinociceptive and toxic effects (convulsions and
hypertension) were abolished by pretreatment with the brain penetrant neuronal nAChR antagonist
mecamylamine (1 mg/kg s.c.; i.v. for cardiovascular studies), demonstrating that these actions of
ABT-594 were mediated via activation of neuronal
nicotinic receptors. Continuous infusion of
ABT-594 (0.2 mg/kg per day s.c.) to rats for 7 days followed by challenge with
mecamylamine (1 mg/kg i.p.) induced a
nicotine-like abstinence syndrome suggesting that
ABT-594 has
nicotine-like dependence liability. These findings indicate that the acute safety profile of
ABT-594 is not significantly improved over other nicotinic
analgesics.